VivoSeq
Metabolic & Endocrine

Diabetic Ulcer

0

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Diabetic Ulcer is an early-stage landscape with 0 programs across 3 companies. The most active players are Abeona Therapeutics, Inc, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Advanced Medical Solutions Ltd..

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Abeona Therapeutics, Inc

0 programs

PreclinicalJohnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

0 programs

PreclinicalA

Advanced Medical Solutions Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed7 · 70%
Unknown status3 · 30%

Clinical Trials

Trial Activity

10 trials

Polydeoxyribonucleotide -Placentex Mastelli(Pdrn) for the Treatment of Diabetic Ulcers
Completed·UUniversity of Messina·Phase 4·NCT00638872·215 enrolled
Evaluation of the Safety Follow-up of Becaplermin or Placebo Gel Following Treatment of Chronic, Full Thickness Diabetic Ulcers
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·N/A·NCT00740922·563 enrolled
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
Completed·AAbeona Therapeutics, Inc·Phase 3·NCT00563394·584 enrolled
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
Completed·AAbeona Therapeutics, Inc·Phase 3·NCT00563433·342 enrolled
Effect of Topic Pirfenidone in Diabetic Ulcers
Completed·IInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·Phase 3·NCT02222376·36 enrolled
Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities
Completed·TTissue Repair Company·Phase 2·NCT00493051·124 enrolled
Post Market Clinical Follow up Study to Confirm the Ongoing Safety and Performance of a Debridement Pad in Superficial, Chronic and Acute Wounds
Completed·AAdvanced Medical Solutions Ltd.·Preclinical·NCT07255937·184 enrolled
Clinical Evaluation and Generalized Application of "Qing-Hua-Bu" Three Dynamic Sequential Therapy of Diabetic Ulcer
Unknown status·SShanghai Yueyang Integrated Medicine Hospital·Phase 2·NCT03574935·150 enrolled
Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers
Unknown status·—·Phase 4·NCT02742233·60 enrolled
Study on Regeneration of Skin Defects in Diabetic Ulcers Treated With New Electrospun Material PLCL/Fg
Unknown status·—·Phase 4·NCT06014437·52 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)